CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 541 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
P162-0948
CAS:P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357CDK2/4-IN-2
CAS:CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.Fórmula:C18H20F3N7O3S2Cor e Forma:SolidPeso molecular:503.52CDK4/9-IN-1
CAS:CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.Fórmula:C22H34N6O2Cor e Forma:SolidPeso molecular:414.544CDK2-IN-39
CAS:CDK2-IN-39 (compound 4) is a CDK2 inhibitor.Fórmula:C14H15N3O4SCor e Forma:SolidPeso molecular:321.352CDK2-IN-40
CAS:CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384Zeltociclib
CAS:Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346CDK7-IN-26
CAS:CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Fórmula:C22H22FN6OPSPeso molecular:468.49GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347CDK4/6-IN-24
CAS:CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Fórmula:C32H41N7O3Cor e Forma:SolidPeso molecular:571.713Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CDK4-IN-1
CAS:CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50Fórmula:C22H29ClN8Pureza:98%Cor e Forma:SolidPeso molecular:440.97CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Fórmula:C21H20F3N7OPureza:98%Cor e Forma:SolidPeso molecular:443.42CDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Fórmula:C19H16ClF3N4O2Cor e Forma:SolidPeso molecular:424.8Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Fórmula:C22H23F4N5OPureza:98.88%Cor e Forma:SolidPeso molecular:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Fórmula:C16H14FN5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:327.31GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.433Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Fórmula:C15H13FN6OCor e Forma:SolidPeso molecular:312.308Tibremciclib
CAS:Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Fórmula:C28H32F2N8Pureza:98%Cor e Forma:SolidPeso molecular:518.6
